What is Zimmer Biomet ROSA?

Zimmer Biomet ROSA: mid-size cross-domain multi-procedure archetype

Zimmer Biomet ROSA (Robotic Surgical Assistant) is a mid-size cross-domain multi-procedure surgical robotic platform from Zimmer Biomet Holdings (NYSE: ZBH). Per DEPLOY's surgical cluster framework, ROSA anchors the mid-size cross-domain multi-procedure platform archetype within the surgical cluster's Wave 3 orthopedic sub-cohort triangle alongside Stryker Mako (large-footprint CT-based) and Smith+Nephew CORI (handheld imageless).

Zimmer Biomet Holdings: NYSE: ZBH

Zimmer Biomet Holdings is a publicly-traded medical-technology company (NYSE: ZBH) with substantial orthopedic + dental + extremities + sports-medicine product portfolios. ROSA operates as Zimmer Biomet's surgical-robotic platform extending across orthopedic + neurosurgical clinical domains.

Cross-domain procedure scope: knee + hip + brain + shoulder

Per Agent A orthopedic ingest, ROSA operates cross-domain multi-procedure scope spanning orthopedics + neurosurgery:

• Knee: orthopedic knee procedures (foundational orthopedic indication).
• Hip (direct-anterior): hip procedures via direct-anterior surgical approach.
• Brain (SEEG/DBS): stereoelectroencephalography (SEEG) + deep brain stimulation (DBS) neurosurgical procedures.
• Shoulder: shoulder procedures.

Per DEPLOY's framework, the cross-domain (orthopedic + neurosurgery) procedure scope is editorially significant: ROSA spans clinical domains that other orthopedic-sub-cohort entries do NOT cover. Stryker Mako is multi-procedure orthopedic + spine + shoulder but does NOT extend into neurosurgery; Smith+Nephew CORI is knee-only robotic (hip navigation-only). The ROSA cross-domain extension into brain + spine-DBS represents a structurally distinct cohort-tier-specialization position.

Acquisition lineage: Medtech SA 2016 (brain technology) + subsequent orthopedic extension

Per Agent A orthopedic ingest, the ROSA lineage operates through:

• Medtech SA acquired 2016: Zimmer Biomet acquired Medtech SA, integrating ROSA brain technology (SEEG + DBS neurosurgical-robotic).
• Subsequent orthopedic extension: ROSA was extended from brain-only to orthopedic procedures (knee + hip + shoulder) via subsequent product development.

Per DEPLOY's framework, the brain-technology-first lineage matters editorially at the entity verification layer: ROSA's orthopedic positioning is an extension of the original neurosurgical-robotic platform, not the inverse. Trade-press coverage framing ROSA as a Zimmer-Biomet-native orthopedic-robotic platform without the Medtech SA + brain-technology origin operates outside Agent A primary-source-anchored verification.

CRITICAL CORRECTION #1: ROSA Spine LEFT Zimmer Biomet in 2022 ZimVie spinoff

Per Agent A orthopedic ingest, ROSA Spine LEFT Zimmer Biomet in the 2022 ZimVie spinoff. ROSA Spine is NOT a current Zimmer Biomet variant. Per DEPLOY's framework, the spinoff correction matters editorially:

• ZimVie spinoff 2022: Zimmer Biomet spun off its dental + spine businesses as ZimVie Inc. (NASDAQ: ZIMV).
• ROSA Spine to ZimVie: the ROSA Spine product line transferred to ZimVie in the spinoff.
• Current ZB ROSA scope: knee + hip + brain + shoulder. NOT spine.

Per cap-flag-as-trust-signal, trade-press coverage listing ROSA Spine as a current Zimmer Biomet variant operates outside Agent A primary-source-anchored verification. The 2022 ZimVie spinoff transferred ROSA Spine out of the Zimmer Biomet portfolio; News Pub should NOT surface ROSA Spine as a current ZB product per Agent A.

CRITICAL CORRECTION #2: ZB autonomy enters via SEPARATE Monogram acquisition, NOT ROSA

Per Agent A orthopedic ingest, Zimmer Biomet's autonomy positioning enters via a SEPARATE Monogram acquisition, NOT ROSA. The Monogram acquisition + ROSA platform are kept distinct in the entity record so the AI-augmented-not-autonomous framing holds across the orthopedic sub-cohort consistently:

• ROSA (current scope): AI-augmented surgeon-controlled assistance; same assistive class as Mako + CORI + Intuitive da Vinci + Moon Maestro.
• Monogram (separate): autonomous-TKA technology entering ZB via separate acquisition; tracked as future-ingest candidate per Agent A flag.

Per DEPLOY's framework, the keep-distinct framing is critical at the cohort verification posture layer: collapsing Monogram autonomy into the ROSA entity record would break the AI-augmented-not-autonomous framing applied consistently across all orthopedic-robotic anchors. Per cap-flag-as-trust-signal, the entity-scope discipline preserves cohort-framework boundary.

AI-augmented surgeon-controlled assistance (NOT autonomous); same class across cohort

Per Agent A orthopedic ingest + DEPLOY's surgical cluster framework, ROSA operates AI-augmented surgeon-controlled assistance, NOT autonomous-robotic surgery: same assistive class as Mako + CORI + Intuitive da Vinci + Moon Maestro. The AI-augmented-not-autonomous framing is applied consistently across the orthopedic sub-cohort triangle (Mako + CORI + ROSA) + broader surgical cluster (+ da Vinci + Maestro + Versius + Ottava).

Per DEPLOY's framework, the consistent framing matters editorially: trade-press coverage framing orthopedic-robotic systems as "autonomous surgical robots" operates outside Agent A primary-source-anchored verification. The Monogram autonomous-TKA technology operates separately + is tracked as future-ingest candidate; ROSA itself remains AI-augmented surgeon-controlled assistance.

Cap-flag: aggregator-installed-base figures conflict

Per cap-flag-as-trust-signal, aggregator-installed-base figures conflict for ROSA across trade-press coverage. Per DEPLOY's framework, specific installed-base counts operate at lower verification posture pending Zimmer Biomet SEC-disclosed primary-source confirmation; the cross-domain multi-procedure clinical scope is the load-bearing verified scope; specific installed-base + per-procedure deployment figures cap-flagged.

Cohort positioning: mid-size cross-domain multi-procedure platform archetype

Per the surgical cluster framework, Zimmer Biomet ROSA anchors:

• Mid-size cross-domain multi-procedure platform archetype: knee + hip + brain + shoulder; spans orthopedics + neurosurgery.
• Wave 3 orthopedic sub-cohort triangle: Mako (large-footprint CT-based) + CORI (handheld imageless) + ROSA (mid-size cross-domain); form-factor + procedure-scope variance axis.
• Two critical corrections preserve cohort verification posture: ROSA Spine NOT current ZB (ZimVie 2022 spinoff); Monogram autonomy separate from ROSA.
• Medtech SA 2016 brain-technology origin + subsequent orthopedic extension: brain-tech-first lineage editorially significant.
• AI-augmented-surgeon-controlled-not-autonomous: consistent framing across orthopedic sub-cohort + broader surgical cluster.

Contrast with cohort:

• Stryker Mako: large-footprint CT-based; multi-procedure orthopedic + spine + shoulder; market-leader positioning.
• Smith+Nephew CORI: handheld imageless; knee-only robotic (hip is navigation-only NOT robotic).
• Intuitive da Vinci: replacement-robotics soft-tissue market-leader.
• Moon Surgical Maestro: assistive-laparoscopy commercial-niche.
• CMR Versius: international commercial soft-tissue modular architecture.

Consumer pricing surface for Zimmer Biomet ROSA is forthcoming via Agent B's planned orthopedic sub-cohort /price triangle; per cap-flag-as-trust-signal, the consumer-price-page is documented as forthcoming honest-absence pending Agent B's ship. Registry institutional depth at Zimmer Biomet registry company + ROSA registry model.

For the canonical surgical cluster context, see the surgical robotics cluster. For the large-footprint orthopedic contrast, see what is Stryker Mako. For the handheld imageless contrast, see what is Smith+Nephew CORI. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Zimmer Biomet ROSA: the 4-way autonomy-boundary taxonomy (AI-augmented operator-controlled tier; mid-size cross-domain) + verified-vs-claimed at within-entity granularity (per-procedure clearances across knee + hip + brain SEEG/DBS + shoulder; CRITICAL CORRECTION ROSA Spine LEFT ZB in 2022 ZimVie spinoff) + the 9-tier source-quality rubric (FDA + ZB SEC source classification).